Skip to content. | Skip to navigation

Garvan Institute

Sections
 

Professor Herbert Herzog

 

Director, Neuroscience Research Program, Garvan Institute of Medical Research; NHMRC Principal Research Fellow; Adjunct Professor, Faculty of Medicine, The University of New South Wales

Email: h.herzog 'at' garvan.org.au
Research Group: Eating Disorders

 
 
Herbert caused his father great dismay, when at the age of 4 ½, he dismantled his pocket watch. Herbert's drive to find out what was going out at the micro-level persisted through his school years, in Austria, and his analytical tendencies led him to university studies in Chemistry. He switched to Biochemistry for his PhD, which he obtained from the University of Innsbruck (Austria).
 
 
 

In 1991, Herbert joined the Garvan Institute and was the first to isolate and characterise a member of the Neuropeptide Y (NPY) receptor family. He has continued to study the molecular biology, genetics and pharmacology of NPY receptors and investigate the numerous functions of neuropeptide signalling. Herbert’s current work focuses mostly on the brain’s role in the regulation of eating behaviour, energy storage and stress.

Education

1996 Habilitation - Priv. Doz. (Doctor of Science), Free University of Berlin (Germany)
1989 Doktorprüfung - Dr. rer. nat., University of Innsbruck (Austria)
1986 Diplomprüfung Chemie - Mag. rer. nat., University of Innsbruck, (Austria)
1980 - 1986 Study of Chemistry, University of Innsbruck, (Austria)

Awards and Honours

2007 NHMRC Principal Research Fellowship (Australia)
2000 Wellcome Trust Short Term Travel Fellowship (UK)
1991 Erwin Schrödinger Fellowship (Austria)

Publications

Johnen H, Lin S, Kuffner T, Brown DA, Tsai VWW, Bauskin AR, Wu L, Pankhurst G, Jiang L, Junankar S, Hunter M, Fairlie W, Lee NJ, Enriquez R, Baldock PA, Corey E, Apple FS, Murakami MM, Lin EJ, Wang C, During MJ, Sainsbury A, Breit* SN  &  Herzog* H Tumour-induced anorexia and weight loss are mediated by the TGF-≤ superfamily cytokine MIC-1.  Nat. Med 2007 13(11):1333-1340.  * equal last author

Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R, Herzog H, Zukowska Z. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13(7):803-11.

Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H, Le Roux CW, Thomas EL, Bell JD, Withers DJ. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006; 4(3):223-33.

Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, Herzog H, Mackay F. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med 2005; 202(11):1527-38.

Karl T, Lin S, Schwarzer C, Sainsbury A, Couzens M, Wittmann W, Boey D, von Horsten S, Herzog H. Increased aggressive behaviour revealed in Y1 knockout mice. P Natl Acad Sci USA 2004; 101(34):12742-12747.

Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. The gut hormone, PYY3-36, physiologically inhibits food intake. Nature 2002; 418:650-654.

Sainsbury A, Schwarzer C, Couzens M, Fetissov S, Fürtinger S, Jenkins A, Cox HM, Sperk G, Hökfelt T, Herzog H. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. P Natl Acad Sci USA 2002; 99:8938-8943.

Sainsbury A, Schwarzer C, Couzens M, Jenkins A, Oakes SR, Ormandy CJ, Herzog H. Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev 2002; 16:1077-1088.

Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002; 109:915-921.

Herzog H, Hort Y, Schneider R, Shine J. Seminalplasmin: recent evolution of a new member of the neuropeptide Y gene family. P Natl Acad Sci USA 1995; 92:594-598.

Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor couples to two different second messenger systems. P Natl Acad Sci USA 1992; 89:5794-5798.

Search for all publications by Herbert Herzog

 
 
 

Areas of Interest

Neuropeptide Y, PYY, Y receptors, neurotransmission, appetite, energy balance, adiposity, obesity, anorexia, cachexia, bone, stress
 

News

 

Low levels of PYY hormone a very early indicator of Type 2 diabetes

MEDIA RELEASE: 10 Mar 2008
Garvan scientists have published findings showing that low levels of the hormone PYY could be used as a predictor for the development of Type 2 diabetes. Clinical studies have shown that people with a family history of Type 2 diabetes, but not yet showing signs of insulin resistance themselves, produce lower levels of PYY after eating, a very early sign of pre-diabetes.
 
 

Natural gut hormones may provide a treatment for obesity

MEDIA RELEASE: 08 Jan 2008
Garvan researchers have shown that a hormone released naturally from the gut could be used to treat obesity and Type 2 diabetes. After a meal, the hormone peptide YY (PYY) is released from the gut and acts on the brain, contributing to a feeling of satiety. Researchers foresee the use of this hormone as a weight loss medication.
 
 

The molecule that can switch appetite off and on

05 Nov 2007
Researchers from the St Vincent’s Campus have identified the molecule responsible for the extreme weight loss common in late stage cancer. The findings published online in Nature Medicine suggest it may soon be possible to prevent this condition, giving people the strength to survive treatment. Conversely, the knowledge also suggests a way to switch off appetite in obese people.
 
 

Personal tools